- Home
- EVAX vs CAPT Comparison
EVAX vs CAPT Comparison
Compare EVAX & CAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- CAPT
- Stock Information
- Founded
- EVAX 2008
- CAPT 2005
- Country
- EVAX Denmark
- CAPT South Korea
- Employees
- EVAX N/A
- CAPT N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- CAPT Blank Checks
- Sector
- EVAX Health Care
- CAPT Finance
- Exchange
- EVAX Nasdaq
- CAPT Nasdaq
- Market Cap
- EVAX 16.3M
- CAPT 16.1M
- IPO Year
- EVAX 2021
- CAPT N/A
- Fundamental
- Price
- EVAX $1.49
- CAPT $0.51
- Analyst Decision
- EVAX Strong Buy
- CAPT
- Analyst Count
- EVAX 2
- CAPT 0
- Target Price
- EVAX $10.00
- CAPT N/A
- AVG Volume (30 Days)
- EVAX 76.2K
- CAPT 1.1M
- Earning Date
- EVAX 05-27-2025
- CAPT 01-01-0001
- Dividend Yield
- EVAX N/A
- CAPT N/A
- EPS Growth
- EVAX N/A
- CAPT N/A
- EPS
- EVAX N/A
- CAPT N/A
- Revenue
- EVAX $3,344,000.00
- CAPT $17,389,944.00
- Revenue This Year
- EVAX $102.45
- CAPT N/A
- Revenue Next Year
- EVAX $100.30
- CAPT N/A
- P/E Ratio
- EVAX N/A
- CAPT N/A
- Revenue Growth
- EVAX 4480.82
- CAPT 84.70
- 52 Week Low
- EVAX $1.20
- CAPT $0.37
- 52 Week High
- EVAX $21.80
- CAPT $5.97
- Technical
- Relative Strength Index (RSI)
- EVAX 43.19
- CAPT 48.71
- Support Level
- EVAX $1.20
- CAPT $0.49
- Resistance Level
- EVAX $1.46
- CAPT $0.51
- Average True Range (ATR)
- EVAX 0.13
- CAPT 0.02
- MACD
- EVAX 0.03
- CAPT 0.00
- Stochastic Oscillator
- EVAX 59.18
- CAPT 36.28
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.